Another practical situation might refer to a dynamic assessment of syndecan-1 in order to evaluate the response to antifibrotic therapies in HF, such as RAAS inhibitors, thus potentially guiding the therapeutic management. This evidence concerns the gene SDC1 and hydrops fetalis.